Year In Review 2016 MPN
Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor, Jakafi® (Ruxolitinib), has led to an effective alleviation of these symptoms in many patients with PV, impacting both disease burden and quality of life. The identification of certain gene conditions that contribute to MPNs have led to improvements in diagnosis and stratifying risk. Ongoing trials will further define the role of JAK inhibitors in MPNs as well as evaluate combination therapies and new targeted therapies.
CancerConnect News coverage of advances in the management of MPNs included the following key developments:
Polycythemia Vera News
- CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
- Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia
- Jakafi Superior to Standard Treatment in Polycythemia Vera
- All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor
- 5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis
- Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression
- Protein Inhibitor INCB039110 Appears Active in Myelofibrosis
MPN Side Effect News
- Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life
- What You Need to Know about Itching and Myeloproliferative Neoplasms
- Ask the Expert: Blood Cancer Treatment Progress & What’s Next
- Ask the Expert: Polycythemia Vera
- Myeloproliferative Neoplasms: When Good Cells Go Bad
Click here for CURRENT MPN NEWS
Learning More About Myeloproliferative Neoplasms
- Sign up for monthly MPN newsletters here.
- Join the CancerConnect online support group to join ongoing discussions with other individuals affected by PV, ET and myelofibrosis here.
- Follow CancerConnect on Facebook and Twitter.
Copyright © 2017 CancerConnect. All Rights Reserved.
More news and in-depth Myeloproliferative Neoplasms MPN information.